Skip to main navigation Skip to main content

Clin Mol Hepatol : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Page Path

2
results for

"Antimitochondrial antibody"

Article category

Keywords

Publication year

"Antimitochondrial antibody"

Editorial

Autoimmune liver disease

Citations

Citations to this article as recorded by  Crossref logo
  • Correspondence to editorial on “Prediction of primary biliary cholangitis among health check-up population with anti-mitochondrial M2 antibody positive”
    Haolong Li, Song Liu, Xu Wang, Li Wang, Tengda Xu, Yongzhe Li
    Clinical and Molecular Hepatology.2025; 31(2): e194.     CrossRef
  • 7,694 View
  • 46 Download
  • 1 Web of Science
  • Crossref
Original Article
Clinical features and prognosis of primary biliary cirrhosis in Korea
Kyung-Ah Kim, M.D.1, Sook-Hyang Jeong, M.D.2, Jung Il Lee, M.D.3, Jong Eun Yeon, M.D.4, Heon Ju Lee, M.D.5, So Young Kwon, M.D.6, U Im Chang, M.D.7, Hyun Ju Min, M.D.8
Korean J Hepatol 2010;16(2):139-146.
Published online June 25, 2010
DOI: https://doi.org/10.3350/kjhep.2010.16.2.139
Background/Aims
This study investigated the clinical features and prognosis of primary biliary cirrhosis (PBC) in Korea. Methods: Clinical data of patients diagnosed as PBC between 1997 and 2008 at eight referral hospitals were analyzed retrospectively. PBC was diagnosed based on liver function tests, presence of serum antimitochondrial antibody (AMA), and histopathological findings. Results: In total, 251 patients (218 females, 33 males, mean age 54 years) were enrolled, and the mean follow-up duration was 33.5 months. At the diagnosis, 61% of the patients were asymptomatic, 12% had decompensated liver cirrhosis, and 98% were positive for AMA. The serum alkaline phosphate (AlP) level was 2.6 times the upper limit of normal, aspartate aminotransferase was 105 U/l, and bilirubin was 2.0 mg/dl. The mean Mayo risk score was 5.5, and the Child-Pugh class was A, B, and C in 79%, 19%, and 2% of the patients, respectively. Ursodeoxycholic acid (UDCA) was used for treatment in 88% of the patients, among which 70% exhibited biochemical responses defined as normalization or a >40% decrease in AlP at 6 months. Eight deaths occurred during the follow-up, the causes were variceal bleeding, hepatic failure, and sepsis. The overall 5-year survival rate was 95%. The poor prognostic factors were being older than 60 years, high bilirubin, low albumin, ascites, high Mayo risk score, Child-Pugh class C, and initial presence of hepatic decompensation. Conclusions: Most patients diagnosed as PBC were asymptomatic, and these patients had a favorable short-term prognosis. The prognosis of PBC was dependent on the initial severity of liver disease.

Citations

Citations to this article as recorded by  Crossref logo
  • Clinical Characteristics and Prognosis of Concomitant Primary Biliary Cholangitis and Autoimmune Diseases: A Retrospective Study
    Yuwei Liu, Kai Han, Chen Liu, Fangfang Duan, Jun Cheng, Song Yang, Alessandro Granito
    Canadian Journal of Gastroenterology and Hepatology.2021;[Epub]     CrossRef
  • Current epidemiology and clinical characteristics of autoimmune liver diseases in South Korea
    Sook-Hyang Jeong
    Clinical and Molecular Hepatology.2018; 24(1): 10.     CrossRef
  • Clinical Features and Response to UDCA Treatment of Primary Biliary Cirrhosis
    Joo Young Kim, Tae Hun Kim, Kwon Yoo, Ye Ji Han, Jeong Eun Choi, Ji Yoon Kim, Min-Sun Cho
    The Ewha Medical Journal.2015; 38(3): 106.     CrossRef
  • Primary biliary cirrhosis: Clinical and laboratory criteria for its diagnosis
    Vasiliy Ivanovich Reshetnyak
    World Journal of Gastroenterology.2015; 21(25): 7683.     CrossRef
  • The Clinical Significance of Simplified Scoring Criteria as a Diagnostic Tool for Overlap Syndrome in Korea
    Min Suk Kim, Young Seok Kim, Sang Gyune Kim, Jin Myung Byun, La Young Yoon, Dong Hoon Han, Jong Joo Moon, Jae-Hyung Nam, Tae-Jin Kim, Sae Hwan Lee, Seung Won Jung, Hong Soo Kim, Boo sung Kim, Hee Kyung Kim
    Korean Journal of Medicine.2013; 84(2): 211.     CrossRef
  • Management of Primary Biliary Cirrhosis
    Kyung-Ah Kim
    Korean Journal of Medicine.2012; 82(1): 32.     CrossRef
  • Beneficial effects of candesartan, an angiotensin‐blocking agent, on compensated alcoholic liver fibrosis ‐ A randomized open‐label controlled study
    Moon Young Kim, Mee Yon Cho, Soon Koo Baik, Phil Ho Jeong, Ki Tae Suk, Yoon Ok Jang, Chang Jin Yea, Jae Woo Kim, Hyun Soo Kim, Sang Ok Kwon, Byung Su Yoo, Jang Young Kim, Min Seob Eom, Seung Hwan Cha, Sei Jin Chang
    Liver International.2012; 32(6): 977.     CrossRef
  • Prognostic indicators in primary biliary cirrhosis: significance of revised IAHG (International Autoimmune Hepatitis Group) score
    Ho Eun Jung, Jae Young Jang, Soung Won Jeong, Jin Nyoung Kim, Hee Yoon Jang, Yun Ju Cho, Sung Ae Woo, Sae Hwan Lee, Sang Gyune Kim, Sang-Woo Cha, Young Seok Kim, Young Deok Cho, Hong Soo Kim, Boo Sung Kim
    Clinical and Molecular Hepatology.2012; 18(4): 375.     CrossRef
  • The diagnosis and treatment of primary biliary cirrhosis
    Kyung-Ah Kim, Sook-Hyang Jeong
    The Korean Journal of Hepatology.2011; 17(3): 173.     CrossRef
  • Prognosis of Korean patients with primary biliary cirrhosis
    Byung-Cheol Song
    The Korean Journal of Hepatology.2010; 16(2): 109.     CrossRef
  • 7,633 View
  • 96 Download
  • Crossref